Kidney Cancer Podcasts Kidney Cancer RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Can renal tumour biopsies prevent unnecessary interventions?
Maxine Tran, Senior lecturer and Honorary Consultant Urologist Specialist center for kidney cancer, Royal Free Hospital UCL Division of Surgery and Interventional Science asks the question "Can renal ... Author: kidneycancer Added: 04/28/2018 (Source: Oncology Tube)
Source: Oncology Tube - April 28, 2018 Category: Cancer & Oncology Source Type: podcasts

Timing of Key Genetic Events In Renal Cancer and Possible Prevention Strategies
Tom Mitchell BMBCh, DPhil, FRCS, Academic Clinical Lecturer & Honorary Urology Registrar, Cambridge University Hospitals discusses Timing of Key Genetic Events In Renal Cancer and Possible Prevention ... Author: kidneycancer Added: 04/28/2018 (Source: Oncology Tube)
Source: Oncology Tube - April 28, 2018 Category: Cancer & Oncology Source Type: podcasts

Screening for kidney cancer: why not?
Grant D Stewart, University Lecturer, University of Cambridge, Consultant Urological Surgeon, Addenbrookes Hospital asks the question "Screening for kidney cancer: why not?" at the 13th European Inte... Author: kidneycancer Added: 04/28/2018 (Source: Oncology Tube)
Source: Oncology Tube - April 28, 2018 Category: Cancer & Oncology Source Type: podcasts

David F. McDermott, MD - A Master Class on Applying Newer Therapies for Renal Cell Carcinoma: Meeting Real Challenges Through the Advanced Disease Continuum
A Master Class on Applying Newer Therapies for Renal Cell Carcinoma: Meeting Real Challenges Through the Advanced Disease Continuum (Source: PeerView CME/CE Audio Podcast - Oncology)
Source: PeerView CME/CE Audio Podcast - Oncology - April 23, 2018 Category: Cancer & Oncology Authors: PVI, PeerView Institute for Medical Education Tags: Science, Medicine Source Type: podcasts

Genomic and Expression Profling Soon to be part of treatment decision making
Walter M. Stadler, MD University of Chicago, discusses Genomic and Expression Profling Soon to be part of treatment decision making at Kidney Cancer Association 2017 in Miami. <br /> Author: kidneycancer Added: 04/03/2018 (Source: Oncology Tube)
Source: Oncology Tube - April 3, 2018 Category: Cancer & Oncology Source Type: podcasts

S1500's Completion May Alter Standard of Care for PRCC Compares 3 pool MET inhibitors to Sutent as a comparator arm
Brian M. Shuch, MD Yale School of Medicine, discusses how S1500's Completion May Alter Standard of Care for PRCC Compares 3 pool MET inhibitors to Sutent as a comparator arm at Kidney Cancer Associat... Author: kidneycancer Added: 04/03/2018 (Source: Oncology Tube)
Source: Oncology Tube - April 3, 2018 Category: Cancer & Oncology Source Type: podcasts

May Select Patients for VEGF or PD-1 Targeted Further investigation in other immunotherapies
Walter M. Stadler, MD University of Chicago, discusses how they May Select Patients for VEGF or PD-1 Targeted Further investigation in other immunotherapies at Kidney Cancer Association 2017 in Miami.... Author: kidneycancer Added: 04/03/2018 (Source: Oncology Tube)
Source: Oncology Tube - April 3, 2018 Category: Cancer & Oncology Source Type: podcasts

The Importance of Statistical Analysis Plans Minimize errors, reduce amount of surprises, & diminish data mining
Maxine Sun, MD Dana-Farber Cancer Institute, discusses The Importance of Statistical Analysis Plans Minimize errors, reduce amount of surprises, & diminish data mining at Kidney Cancer Association 2... Author: kidneycancer Added: 04/03/2018 (Source: Oncology Tube)
Source: Oncology Tube - April 3, 2018 Category: Cancer & Oncology Source Type: podcasts

Role of Government in Health Care Political climate raises questions on health care as a right
Robert Uzzo, MD Fox Chase Cancer Center, discusses the Role of Government in Health Care Political climate raises questions on health care as a right at Kidney Cancer Association 2017 in Miami. Author: kidneycancer Added: 04/03/2018 (Source: Oncology Tube)
Source: Oncology Tube - April 3, 2018 Category: Cancer & Oncology Source Type: podcasts

Biomarker Data From Phase II Trial Preliminary expression profiling
Walter M. Stadler, MD University of Chicago, discusses Biomarker Data From Phase II Trial Preliminary expression profiling at Kidney Cancer Association 2017 in Miami. Author: kidneycancer Added: 04/03/2018 (Source: Oncology Tube)
Source: Oncology Tube - April 3, 2018 Category: Cancer & Oncology Source Type: podcasts

SWOG S1500 - Randomized Phase II Trial Efficacy assessment of multiple MET kinase inhibitors in metastatic PRCC
Brian M. Shuch, MD Yale School of Medicine, discusses the SWOG S1500 - Randomized Phase II Trial Efficacy assessment of multiple MET kinase inhibitors in metastatic PRCC at Kidney Cancer Association 2... Author: kidneycancer Added: 04/03/2018 (Source: Oncology Tube)
Source: Oncology Tube - April 3, 2018 Category: Cancer & Oncology Source Type: podcasts

Challenges of VEGF & amp; Immunotherapy Combinations Resistance patterns in patients disease progression
Tian Zhang, MD Duke University Medical Center, explains the Challenges of VEGF &amp; Immunotherapy Combinations Resistance patterns in patients disease progression at Kidney Cancer Association 2017 ... Author: kidneycancer Added: 04/03/2018 (Source: Oncology Tube)
Source: Oncology Tube - April 3, 2018 Category: Cancer & Oncology Source Type: podcasts

Value is a Function of Outcomes and Cost Optimal care is not always related to more or less expensive care
Robert Uzzo, MD Fox Chase Center, explains how Value is a Function of Outcomes and Cost Optimal care is not always related to more or less expensive care at Kidney Cancer Association 2017 in Miami. Author: kidneycancer Added: 04/03/2018 (Source: Oncology Tube)
Source: Oncology Tube - April 3, 2018 Category: Cancer & Oncology Source Type: podcasts

Biomarker Data From Phase II Randomized Trial Study of Atezolizumab With or Without Bevacizumab v Sunitinib
Walter M. Stadler, MD University of Chicago, discusses Biomarker Data From Phase II Randomized Trial Study of Atezolizumab With or Without Bevacizumab v Sunitinib at Kidney Cancer Association 2017 in... Author: kidneycancer Added: 04/03/2018 (Source: Oncology Tube)
Source: Oncology Tube - April 3, 2018 Category: Cancer & Oncology Source Type: podcasts

Difference Between Type 1 & 2 PRCC Although look similar on light microscopy, they have different biology
Brian M. Shuch, MD Yale School of Medicine, discusses the Difference Between Type 1 & 2 PRCC Although look similar on light microscopy, they have different biology at Kidney Cancer Association 2017 i... Author: kidneycancer Added: 04/03/2018 (Source: Oncology Tube)
Source: Oncology Tube - April 3, 2018 Category: Cancer & Oncology Source Type: podcasts